ALBIREO PHARMA INC (ALBO) Stock Fundamental Analysis

NASDAQ:ALBO • US01345P1066

44.15 USD
-0.1 (-0.23%)
At close: Mar 2, 2023
44.33 USD
+0.18 (+0.41%)
After Hours: 3/2/2023, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

ALBO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 521 industry peers in the Biotechnology industry. While ALBO seems to be doing ok healthwise, there are quite some concerns on its profitability. ALBO shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ALBO has reported negative net income.
  • ALBO had a negative operating cash flow in the past year.
ALBO Yearly Net Income VS EBIT VS OCF VS FCFALBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

  • ALBO has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBO Yearly ROA, ROE, ROICALBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 -20 -40 -60

1.3 Margins

  • With an excellent Gross Margin value of 95.56%, ALBO belongs to the best of the industry, outperforming 95.92% of the companies in the same industry.
  • ALBO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALBO Yearly Profit, Operating, Gross MarginsALBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • ALBO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ALBO has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ALBO has an improved debt to assets ratio.
ALBO Yearly Shares OutstandingALBO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 5M 10M 15M
ALBO Yearly Total Debt VS Total AssetsALBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

  • ALBO has an Altman-Z score of 0.32. This is a bad value and indicates that ALBO is not financially healthy and even has some risk of bankruptcy.
  • ALBO has a Altman-Z score (0.32) which is comparable to the rest of the industry.
  • There is no outstanding debt for ALBO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACC9.04%
ALBO Yearly LT Debt VS Equity VS FCFALBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 50M -50M 100M -100M 150M

2.3 Liquidity

  • A Current Ratio of 6.32 indicates that ALBO has no problem at all paying its short term obligations.
  • ALBO has a Current ratio (6.32) which is comparable to the rest of the industry.
  • A Quick Ratio of 6.23 indicates that ALBO has no problem at all paying its short term obligations.
  • ALBO has a Quick ratio (6.23) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 6.32
Quick Ratio 6.23
ALBO Yearly Current Assets VS Current LiabilitesALBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • ALBO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.52%, which is quite good.
  • The Revenue has grown by 432.29% in the past year. This is a very strong growth!
  • Measured over the past years, ALBO shows a very strong growth in Revenue. The Revenue has been growing by 47.13% on average per year.
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
Revenue 1Y (TTM)432.29%
Revenue growth 3Y47.13%
Revenue growth 5YN/A
Sales Q2Q%168.34%

3.2 Future

  • The Earnings Per Share is expected to grow by 24.17% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 84.10% on average over the next years. This is a very strong growth
EPS Next Y-20.91%
EPS Next 2Y0.48%
EPS Next 3Y13.05%
EPS Next 5Y24.17%
Revenue Next Year69.42%
Revenue Next 2Y72.94%
Revenue Next 3Y92.77%
Revenue Next 5Y84.1%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALBO Yearly Revenue VS EstimatesALBO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
ALBO Yearly EPS VS EstimatesALBO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ALBO. In the last year negative earnings were reported.
  • Also next year ALBO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBO Price Earnings VS Forward Price EarningsALBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBO Per share dataALBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

  • ALBO's earnings are expected to grow with 13.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.48%
EPS Next 3Y13.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for ALBO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

ALBIREO PHARMA INC

NASDAQ:ALBO (3/2/2023, 8:00:01 PM)

After market: 44.33 +0.18 (+0.41%)

44.15

-0.1 (-0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27
Earnings (Next)05-15
Inst Owners0%
Inst Owner Change0%
Ins Owners0.73%
Ins Owner Change0%
Market Cap915.89M
Revenue(TTM)57.39M
Net Income(TTM)-131.15M
Analysts76.92
Price Target42.84 (-2.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.7%
Min EPS beat(2)-78.3%
Max EPS beat(2)-21.09%
EPS beat(4)1
Avg EPS beat(4)-14.16%
Min EPS beat(4)-78.3%
Max EPS beat(4)58.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.45%
Min Revenue beat(2)0.99%
Max Revenue beat(2)7.92%
Revenue beat(4)3
Avg Revenue beat(4)37.1%
Min Revenue beat(4)-15.88%
Max Revenue beat(4)155.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.11%
PT rev (3m)-28.41%
EPS NQ rev (1m)-7.4%
EPS NQ rev (3m)-7.4%
EPS NY rev (1m)-1.4%
EPS NY rev (3m)-17.75%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)-0.4%
Revenue NY rev (1m)-1.08%
Revenue NY rev (3m)-0.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.96
P/FCF N/A
P/OCF N/A
P/B 9.15
P/tB 11.06
EV/EBITDA N/A
EPS(TTM)-6.72
EYN/A
EPS(NY)-6.71
Fwd EYN/A
FCF(TTM)-5.61
FCFYN/A
OCF(TTM)-5.56
OCFYN/A
SpS2.77
BVpS4.82
TBVpS3.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.56%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 223.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.32
Quick Ratio 6.23
Altman-Z 0.32
F-Score3
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)209.07%
Cap/Depr(5y)244.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
EPS Next Y-20.91%
EPS Next 2Y0.48%
EPS Next 3Y13.05%
EPS Next 5Y24.17%
Revenue 1Y (TTM)432.29%
Revenue growth 3Y47.13%
Revenue growth 5YN/A
Sales Q2Q%168.34%
Revenue Next Year69.42%
Revenue Next 2Y72.94%
Revenue Next 3Y92.77%
Revenue Next 5Y84.1%
EBIT growth 1Y7.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.31%
OCF growth 3YN/A
OCF growth 5YN/A

ALBIREO PHARMA INC / ALBO FAQ

What is the ChartMill fundamental rating of ALBIREO PHARMA INC (ALBO) stock?

ChartMill assigns a fundamental rating of 4 / 10 to ALBO.


Can you provide the valuation status for ALBIREO PHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to ALBIREO PHARMA INC (ALBO). This can be considered as Overvalued.


What is the profitability of ALBO stock?

ALBIREO PHARMA INC (ALBO) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ALBIREO PHARMA INC?

The Earnings per Share (EPS) of ALBIREO PHARMA INC (ALBO) is expected to decline by -20.91% in the next year.